DK2970383T3 - Fremgangsmåde til behandling af fibrose - Google Patents
Fremgangsmåde til behandling af fibrose Download PDFInfo
- Publication number
- DK2970383T3 DK2970383T3 DK14762435.7T DK14762435T DK2970383T3 DK 2970383 T3 DK2970383 T3 DK 2970383T3 DK 14762435 T DK14762435 T DK 14762435T DK 2970383 T3 DK2970383 T3 DK 2970383T3
- Authority
- DK
- Denmark
- Prior art keywords
- treating fibrosis
- fibrosis
- treating
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361800117P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/030147 WO2014145389A1 (en) | 2013-03-15 | 2014-03-17 | Inhibition of pulmonary fibrosis with nutlin-3a and peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2970383T3 true DK2970383T3 (da) | 2021-07-05 |
Family
ID=51537978
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK14762435.7T DK2970383T3 (da) | 2013-03-15 | 2014-03-17 | Fremgangsmåde til behandling af fibrose |
| DK21168926.0T DK3929207T3 (da) | 2013-03-15 | 2014-03-17 | Peptid fttftvt til anvendelse i behandling af fibrose |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK21168926.0T DK3929207T3 (da) | 2013-03-15 | 2014-03-17 | Peptid fttftvt til anvendelse i behandling af fibrose |
Country Status (11)
| Country | Link |
|---|---|
| US (8) | US9630990B2 (https=) |
| EP (3) | EP4438044A3 (https=) |
| JP (4) | JP6603207B2 (https=) |
| KR (3) | KR102588702B1 (https=) |
| CN (3) | CN110201144B (https=) |
| AU (3) | AU2014233055B2 (https=) |
| CA (1) | CA2904870C (https=) |
| DK (2) | DK2970383T3 (https=) |
| ES (2) | ES2875853T3 (https=) |
| PT (2) | PT3929207T (https=) |
| WO (1) | WO2014145389A1 (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| ES2579909T3 (es) | 2009-02-03 | 2016-08-17 | Koninklijke Nederlandse Akademie Van Wetenschappen | Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre |
| CN110201144B (zh) * | 2013-03-15 | 2024-01-02 | 得克萨斯州大学系统董事会 | 用Nutlin-3a和肽抑制肺纤维化 |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| AU2015211021B2 (en) | 2014-01-28 | 2020-07-02 | Buck Institute For Research On Aging | Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| AU2015261380B2 (en) | 2014-05-16 | 2021-04-15 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved culture method for organoids |
| GB201421092D0 (en) * | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
| GB201421094D0 (en) | 2014-11-27 | 2015-01-14 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium |
| WO2016138413A1 (en) * | 2015-02-27 | 2016-09-01 | Board Of Regents, The University Of Texas System | Polypeptide therapeutics and uses thereof |
| GB201603569D0 (en) | 2016-03-01 | 2016-04-13 | Koninklijke Nederlandse Akademie Van Wetenschappen | Improved differentiation method |
| WO2018190680A1 (ko) * | 2017-04-13 | 2018-10-18 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 뉴트린-3α 및 피53 발현 조절 조성물 또는 방법 |
| KR102082285B1 (ko) * | 2017-04-13 | 2020-02-28 | 충남대학교산학협력단 | 세포내 결핵균 제어를 위한 Nutlin-3α (뉴트린-3α) 및 p53 발현 조절 조성물 또는 방법 |
| CN107987128B (zh) | 2017-11-17 | 2019-06-11 | 广东医科大学 | 一种功能多肽及其在制备防治肺纤维化药物中的应用 |
| GB201721615D0 (en) | 2017-12-21 | 2018-02-07 | Koninklijke Nederlandse Akademie Van Wetenschappen | Immune cell organoid co-cultures |
| US12281180B2 (en) | 2018-07-13 | 2025-04-22 | New York University | Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same |
| KR20210057127A (ko) | 2018-09-10 | 2021-05-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 카베올린-1 펩티드의 건조 분말 제형 및 이의 사용 방법 |
| AU2019339260B2 (en) | 2018-09-10 | 2025-06-26 | Rein Therapeutics, Inc. | Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis |
| CN109010798A (zh) * | 2018-09-17 | 2018-12-18 | 中山大学中山眼科中心 | 一种多肽的新用途 |
| GB201819224D0 (en) | 2018-11-26 | 2019-01-09 | Koninklijke Nederlandse Akademie Van Wetenschappen | Hepatocyte expansion methods |
| EP4086275A4 (en) * | 2019-12-31 | 2024-04-17 | Xiamen University | Multimerization delivery system for intracellular delivery of molecule |
| US20250076312A1 (en) | 2021-02-25 | 2025-03-06 | Lung Therapeutics, Llc | Biomarkers for the treatment of interstitial lung disease |
| WO2022217037A1 (en) * | 2021-04-09 | 2022-10-13 | Board Of Regents, The University Of Texas System | Compositions and methods for treatment of chronic lung diseases |
| CN119258210A (zh) * | 2023-07-06 | 2025-01-07 | 厦门大学 | 新型疫苗递送体系 |
| CN116789751B (zh) * | 2023-08-22 | 2023-11-17 | 中国农业大学 | 预防和/或治疗纤维化疾病的多肽及其应用 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
| CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
| US4021387A (en) | 1975-11-19 | 1977-05-03 | President And Fellows Of Harvard College | Eosinophilotactic tetrapeptides |
| US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
| US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
| CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
| US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
| US4816449A (en) | 1984-08-09 | 1989-03-28 | Immunetech Pharmaceuticals | Immunotherapeutic anti-inflammatory peptide agents |
| US4613676A (en) * | 1983-11-23 | 1986-09-23 | Ciba-Geigy Corporation | Substituted 5-amino-4-hydroxyvaleryl derivatives |
| ZA846192B (en) | 1984-08-09 | 1986-03-26 | Merck Patent Gmbh | Immunotherapeutic polypeptide agents |
| US5728680A (en) | 1987-12-30 | 1998-03-17 | Cytoven J.V. | Methods for normalizing numbers of lymphocytes |
| DK53291D0 (da) * | 1991-03-25 | 1991-03-25 | Carlbiotech Ltd As | Smaa peptider og peptidrelaterede stoffer samt farmaceutiske praeparater indeholdende saadanne forbindelser |
| JP3401005B2 (ja) * | 1992-12-11 | 2003-04-28 | ユニバーシティ オブ フロリダ | 有害生物の防除のための材料および方法 |
| US5559209A (en) * | 1993-02-18 | 1996-09-24 | The General Hospital Corporation | Regulator regions of G proteins |
| US6126939A (en) | 1996-09-03 | 2000-10-03 | Yeda Research And Development Co. Ltd. | Anti-inflammatory dipeptide and pharmaceutical composition thereof |
| US6017735A (en) | 1997-01-23 | 2000-01-25 | Marie Curie Cancer Care | Materials and methods for intracellular transport and their uses |
| US20030113271A1 (en) | 1997-01-29 | 2003-06-19 | University Technology Corporation | Formulations for pulmonary delivery |
| EP1076091A1 (en) * | 1999-08-09 | 2001-02-14 | Universite Catholique De Louvain | Medicament for the prevention and/or the treatment of ischemic heart and peripheral vascular diseases, tumour and wounds |
| US20020077283A1 (en) | 2000-09-08 | 2002-06-20 | Sessa William C. | Caveolin peptides and their use as therapeutics |
| WO2002053161A1 (en) | 2000-12-29 | 2002-07-11 | Alteon, Inc. | Method for treating fibrotic diseases or other indications |
| GB0119852D0 (en) | 2001-08-15 | 2001-10-10 | Univ York | Baculovirus |
| BR0215157A (pt) | 2001-12-18 | 2004-10-19 | Hoffmann La Roche | Cis-2,4,5-trifenil-imidazolinas e seu uso no tratamento de tumores |
| US7625865B2 (en) | 2004-03-26 | 2009-12-01 | Universita Degli Studi Di Parma | Insulin highly respirable microparticles |
| CN101022830A (zh) * | 2004-05-25 | 2007-08-22 | 阿特努奥恩公司 | 抑制下游 u P A R相互作用并结合了尿激酶类纤溶酶原激发剂（ u P A）与其受体（ u P A R）的复合物的配位体：在诊断或治疗中的识别和用途 |
| US7893278B2 (en) | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| TWI299993B (en) | 2005-12-15 | 2008-08-21 | Dev Center Biotechnology | Aqueous inhalation pharmaceutical composition |
| US8058227B2 (en) * | 2006-10-03 | 2011-11-15 | Medical University Of South Carolina | Method of treating fibrosis in a subject in need thereof comprising administering a composition comprising a CSD |
| EP2074142A4 (en) | 2006-10-19 | 2010-10-27 | Angiochem Inc | COMPOUNDS FOR STIMULATING THE FUNCTION OF P-GLYCOPROTEIN AND APPLICATIONS THEREOF |
| CN102131827A (zh) | 2007-12-13 | 2011-07-20 | 葛兰素集团有限公司 | 用于肺部传递给药的组合物 |
| WO2009079692A1 (en) * | 2007-12-21 | 2009-07-02 | Fibrotech Therapeutics Pty Ltd | Halogenated analogues of anti-fibrotic agents |
| WO2009111625A2 (en) | 2008-03-05 | 2009-09-11 | Board Of Regents, The University Of Texas System | Peptide inhibition of lung epithelial apoptosis and pulmonary fibrosis |
| JP5859307B2 (ja) | 2008-09-10 | 2016-02-10 | ジェネンテック， インコーポレイテッド | 眼の血管新生を阻害する方法 |
| GB2466121B (en) | 2008-12-15 | 2010-12-08 | Amira Pharmaceuticals Inc | Antagonists of lysophosphatidic acid receptors |
| PT3501499T (pt) | 2010-02-11 | 2022-11-22 | Ablynx Nv | Métodos e composições para a preparação de aerossóis |
| EP2635686B1 (en) | 2010-11-05 | 2018-03-28 | The Regents of The University of California | Neuronal specific targeting of caveolin expression to restore synaptic signaling and improve cognitive function in the neurodegenerative brain and motor function in spinal cord |
| WO2013184482A1 (en) | 2012-06-04 | 2013-12-12 | Yale University | Method of treating and preventing ocular angiogenesis |
| BR112015022831A2 (pt) | 2013-03-13 | 2017-08-22 | Forest Laboratories Holdings Ltd | Composições farmacêuticas micronizadas |
| CN110201144B (zh) | 2013-03-15 | 2024-01-02 | 得克萨斯州大学系统董事会 | 用Nutlin-3a和肽抑制肺纤维化 |
| MX2016005720A (es) | 2013-11-04 | 2016-11-25 | Univ Texas | Composiciones y metodos para administracion de una enzima a las vias respiratorias de un sujeto. |
| WO2015080980A2 (en) | 2013-11-26 | 2015-06-04 | E&B Technologies Llc | Treatment of autoimmune and/or inflammatory disease using novel caveolin modulators |
| WO2015080943A1 (en) | 2013-11-26 | 2015-06-04 | Yale University | Novel cell-penetrating compositions and methods using same |
| KR20210057127A (ko) | 2018-09-10 | 2021-05-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 카베올린-1 펩티드의 건조 분말 제형 및 이의 사용 방법 |
| AU2019339260B2 (en) | 2018-09-10 | 2025-06-26 | Rein Therapeutics, Inc. | Modified peptide fragments of Cav-1 protein and the use thereof in the treatment of fibrosis |
-
2014
- 2014-03-17 CN CN201910393777.1A patent/CN110201144B/zh active Active
- 2014-03-17 CA CA2904870A patent/CA2904870C/en active Active
- 2014-03-17 JP JP2016503339A patent/JP6603207B2/ja active Active
- 2014-03-17 KR KR1020217018508A patent/KR102588702B1/ko active Active
- 2014-03-17 KR KR1020237034239A patent/KR20230148263A/ko not_active Withdrawn
- 2014-03-17 KR KR1020157025554A patent/KR102268883B1/ko active Active
- 2014-03-17 EP EP24188856.9A patent/EP4438044A3/en active Pending
- 2014-03-17 WO PCT/US2014/030147 patent/WO2014145389A1/en not_active Ceased
- 2014-03-17 AU AU2014233055A patent/AU2014233055B2/en active Active
- 2014-03-17 CN CN201480016012.1A patent/CN105263948B/zh active Active
- 2014-03-17 ES ES14762435T patent/ES2875853T3/es active Active
- 2014-03-17 PT PT211689260T patent/PT3929207T/pt unknown
- 2014-03-17 DK DK14762435.7T patent/DK2970383T3/da active
- 2014-03-17 PT PT147624357T patent/PT2970383T/pt unknown
- 2014-03-17 EP EP21168926.0A patent/EP3929207B1/en active Active
- 2014-03-17 EP EP14762435.7A patent/EP2970383B1/en active Active
- 2014-03-17 DK DK21168926.0T patent/DK3929207T3/da active
- 2014-03-17 US US14/775,895 patent/US9630990B2/en active Active
- 2014-03-17 ES ES21168926T patent/ES2993671T3/es active Active
- 2014-03-17 CN CN202311699535.8A patent/CN117679487A/zh active Pending
-
2017
- 2017-03-10 US US15/455,670 patent/US10377796B2/en active Active
- 2017-10-09 US US15/727,828 patent/US20180086791A1/en not_active Abandoned
-
2018
- 2018-07-12 AU AU2018205157A patent/AU2018205157A1/en not_active Abandoned
- 2018-07-17 JP JP2018134098A patent/JP6975690B2/ja active Active
-
2019
- 2019-12-03 US US16/702,101 patent/US11161875B2/en active Active
-
2020
- 2020-05-15 AU AU2020203192A patent/AU2020203192A1/en not_active Abandoned
-
2021
- 2021-08-05 JP JP2021128989A patent/JP7378833B2/ja active Active
- 2021-10-12 US US17/499,859 patent/US11780879B2/en active Active
-
2022
- 2022-12-02 US US18/061,084 patent/US20230100467A1/en not_active Abandoned
-
2023
- 2023-08-15 US US18/450,056 patent/US12173089B2/en active Active
- 2023-10-25 JP JP2023183297A patent/JP2023178440A/ja active Pending
-
2024
- 2024-11-08 US US18/941,370 patent/US20250304619A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2970383T3 (da) | Fremgangsmåde til behandling af fibrose | |
| IL256514B (en) | Payload dispensing system | |
| IL249981A0 (en) | Method | |
| DK3110988T3 (da) | Metoder til behandling af lithiumholdige materialer | |
| LT3074534T (lt) | Būdai, skirti polinukleotido sekoskaitai | |
| DK3316703T3 (da) | Fremgangsmåde til forbedring af dyrs ydeevne | |
| EP2992997A4 (en) | METHOD OF ABROADING | |
| DK3083540T3 (da) | Fremgangsmåde til fremstilling af substituerede phenoxyphenylketoner | |
| DK3013544T3 (da) | Fremgangsmåde til betonfremstilling | |
| EP2937552A4 (en) | ROCKET MOTOR, ROCKET AND METHOD FOR STARTING A ROCKET MOTOR | |
| DK2857019T3 (da) | Fremgangsmåde til behandling af multipel sklerose | |
| IL244075A (en) | Method for making an electrolyzer apparatus | |
| DK2956071T3 (da) | Sæt til perifer nerveblokering | |
| DK3044788T3 (da) | Ikke-uniform parameterkvantificering til avanceret kobling | |
| BR112015029436A2 (pt) | método de modificação de polímeros | |
| BR112015021083A2 (pt) | método | |
| BR112015029076A2 (pt) | método | |
| DK3016682T3 (da) | Metoder til behandling af kræft | |
| FI20135361L (fi) | Analyyttinen menetelmä | |
| DK2837678T3 (da) | Fremgangsmåde til forbedret afsmeltning | |
| FI20135226L (fi) | Prosessi bioöljyn modifioimiseksi | |
| DK2986325T3 (da) | Fremgangsmåder til behandling af forstyrrelser i urinstofcyklus | |
| DK3047025T3 (da) | Fremgangsmåde til fremstilling af kappevira | |
| DK3042205T3 (da) | Fremgangsmåde til forbedring af antistofstabilitet | |
| DK3047028T3 (da) | Fermenteringsfremgangsmåde |